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Abstract: Ex vivo lung perfusion (EVLP) is an emerging procedure that allows organ preservation, 
assessment and reconditioning, increasing the number of marginal donor lungs for transplantation. 
However, physiological and airflow measurements are unable to unveil the molecular mechanisms 
responsible of EVLP beneficial effects on lung graft and monitor the proper course of the treatment. 
Thus, it is urgent to find specific biomarkers that possess these requirements but also accurate and 
reliable techniques that identify them. The purpose of this study is to give an overview on the 
potentiality of shotgun proteomic platforms in characterizing the status and the evolution of 
metabolic pathways during EVLP in order to find new potential EVLP-related biomarkers. A 
nanoLC-MS/MS system was applied to the proteome analysis of lung tissues from an optimized rat 
model in three experimental groups: native, pre- and post-EVLP. Technical and biological 
repeatability were evaluated and, together with clustering analysis, underlined the good quality of 
data produced. In-house software and bioinformatics tools allowed the label-free extraction of 
differentially expressed proteins among the three examined conditions and the network 
visualization of the pathways mainly involved. These promising findings encourage further 
proteomic investigations of the molecular mechanisms behind EVLP procedure. 
Keywords: proteomics; Ex Vivo Lung Perfusion (EVLP); nanoLC-MS/MS; transplantation 
 
1. Introduction 
Ex vivo lung perfusion (EVLP) is an emerging procedure proposed for organ preservation and 
reconditioning which can increase the number of lungs available for transplantation without 
compromising its success [1]. In fact, it permits the evaluation and the treatment of lungs of doubtful 
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function, such as ones from donors after cardiac death or from high risk donors, not only expanding 
the pool of possible transplants but also improving patient outcomes [2,3]. 
This derives from the fact that organs, previously considered unsuitable for transplantation, 
thanks to EVLP are now safely used and show similar or even better performances than those of 
lungs transplanted immediately after procurement. In these circumstances, EVLP application could 
represent a benefit for all donor lungs prior to implantation (so that it could be inserted in routine 
transplant protocols), but the evidence-based medical data collected so far are still insufficient [4] and 
there are different EVLP systems and application procedures adopted worldwide [5–7]. These 
weaknesses emerged on the basis of lung function measurements, but further research and tools are 
needed to obtain a deeper comprehension of the biological actions exerted by EVLP not only at the 
functional but also at the molecular level. 
Accordingly, there is the need to find clinical and molecular targets that could provide evidence 
to recommend a specific protocol, to monitor the proper course of treatment and predict donor lung 
performance during EVLP procedure and after transplantation. Despite the emergence of EVLP 
technology, currently available methods employed for the evaluation of this procedure, are limited 
to airway and pulmonary measurements and therefore inadequate in assessing EVLP procedure 
monitoring and its molecular effects on lung graft [8]. In addition, the same respiratory diseases, for 
which lung transplantation is the only possible therapy, are a class of highly heterogeneous and 
multifactorial disorders that often make early screening, diagnosis, prognosis, disease progression, 
and treatment effect challenging with the diagnostic techniques applied so far. In fact, traditional 
methods based on reactive medicine (physiological examinations, medical history and airflow 
measurements) are not sufficient to fully satisfy these requirements. 
All these factors contributed to the urgency in finding new specific molecular and clinical 
biomarkers that could be considered as objective diagnostic parameters by clinicians. In the new era 
of medicine [8,9], biomarkers play an essential role, because they summarize a precise biological state 
and provide quantifiable and comparable features that represent indicator of normal state, 
pathogenic processes or therapeutic response [10]. Certainly, thanks also to rapid development of 
next generation sequencing techniques (NGS) genomics approach is the first to be widely applied for 
the identification of genes as molecular biomarkers of diseases and for the selection of personalized 
patient therapies [11,12]. However, the genome only provides theoretical information of the protein 
levels while the proteome describes its actual content, which ultimately determines the phenotype. 
For this reason, genomic/transcriptomic investigations are recently giving way to proteomic 
approaches for a deepened and a more precise characterization of biological processes related to 
different clinical phenotypes and for the molecular monitoring of markers involved in respiratory 
diseases, such as COPD [13,14], cystic fibrosis [15], rhinitis [16], and the effect of anti-IgE therapy [17]. 
Solid organ transplantation represents an interesting challenge to test the potential of the 
proteomics approach and the first attempts to find new potential EVLP-related biomarkers were 
made by analyzing the perfusate protein expression during EVLP with multiplex immunoassays [18–
20]. In these studies, the attention was exclusively focused on a specific class of proteins involved in 
inflammatory processes related to the transplant procedure. 
Indeed, it is important to evaluate if these processes and other lung biological responses are 
effectively due to EVLP-induced changes and not to reconditioning mechanisms that could occur 
during the ex vivo perfusion procedure. To this end, our coauthors of Fondazione IRCCS Cà Granda 
Ospedale Maggiore Policlinico of Milan developed a rat model [21] that reproduces a prolonged ex 
vivo perfusion on uninjured lungs without the use of anti-inflammatory drugs. With gene expression 
studies on lung tissues and the assessment of mediators and metabolites on perfusate, they 
demonstrated that EVLP broadly affects the transcriptional profile and signaling pathways under 
monitoring [22]. 
In this context, the present work represents another step forward in our understanding of lung 
biological response under ex vivo perfusion, employing the same rat model and taking advantage of 
innovative proteomic technologies. In fact, advances in proteomic approaches, especially those which 
are mass spectrometry (MS)-based [23–27], could provide new tools to overcome the lack of 
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sensitivity and specificity of traditional diagnostic techniques, and to detect more than few proteins 
simultaneously in a great dynamic range of concentration and in a wide variety of bio specimens 
[17,28]. 
Our main focus is to develop a shotgun label-free platform based on a nano-chip LC system 
combined to an Orbitrap mass spectrometer benchtop as proof of principle to characterize the 
complete proteome of frozen lung tissues derived from optimized EVLP rat models [21] stratified in 
three experimental conditions: lung biopsies collected from animals in resting conditions (native 
group), lung biopsies taken after death induction, in situ cold perfusion and lung procurement (pre-
EVLP group), and at the end of ex vivo perfusion (post-EVLP group). An added value to this 
approach is given by the application of in-house software and powerful bioinformatics tools that 
facilitate large scale analyses, allowing the detection and validation of differentially expressed 
proteins as potential biomarkers of biological EVLP-induced states and the identification of metabolic 
pathways in which they are involved [29–33]. Finally, the comparison of data obtained from frozen 
and formalin-fixed paraffin-embedded (FFPE) tissues is also performed with the aim to point out all 
the potential of the platform proposed, considering the wide availability of those tissues in clinical 
biobanks [34]. 
2. Results 
The application of a shotgun label-free platform, based on a nanochip LC system combined to a 
hybrid quadrupole Orbitrap mass spectrometer, allowed the direct analysis of lung samples obtained 
from a reproducible EVLP animal model and in three distinct conditions: native, pre-EVLP and post-
EVLP. Specifically, each experimental condition was evaluated using five animals (biological 
replicates) and separately analyzed in duplicate (technical replicates), for a total of thirty nanoLC-
MS/MS runs from which it was possible to identify proteins and perform label-free semiquantitative 
evaluation, cluster and network analyses (Figure 1). 
 
Figure 1. Experimental pipeline. Applied workflow for proteomic investigation of frozen and 
formalin-fixed paraffin-embedded (FFPE) lung tissues derived from an optimized ex vivo lung 
perfusion (EVLP) rat model. (A) Three distinct conditions (n = 5 for each group), native (lungs 
procured from animals in resting conditions), pre-EVLP (lungs subjected to in situ cold flushing and 
then procured), and post-EVLP (lungs subjected to in situ cold flushing, procurement and then to ex 
vivo perfusion/ventilation), were analyzed. (B) After protein extraction and digestion, the obtained 
peptide mixture was analyzed by a nanoLC-MS/MS system in order to allow protein identification 
and label-free semiquantitative data handling, such as repeatability, extraction of differentially 
expressed and discriminant proteins and systems biology analysis. 
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2.1. Surgical Procedures and Physiological Assessments 
As shown in Supplementary Table S1, mean time intervals of warm and cold ischemia were 
similar among animals of the post-EVLP group. Conversely, agonal phase timespan was significantly 
longer in the rat IE9 compared to other animals of the same experimental group (Grubb’s test, p < 
0.05). 
Lung functionality was evaluated through assessment of hemodynamic and respiratory 
parameters and measurement of the perfusate composition throughout the EVLP procedure. 
Pulmonary artery pressure (PAP) significantly increased (p < 0.003), whereas peak inspiratory 
pressure (Ppeak) decreased following recruitment maneuvers (p < 0.001). In addition, gas analysis 
showed that, together with a decrease in glucose concentration (p = 0.003), there was a rise of lactate 
up to 0.7 mmol/L (p < 0.001) (Figure 2). 
Finally, the lung edema index of the Post-EVLP group was not significantly different compared 
to the pre-EVLP and the native groups (p = 0.094). 
 
Figure 2. Evaluation of lung function during EVLP procedure. (a) PAP, significantly increased (p < 
0.003), and (b) Ppeak, decreased following recruitment maneuvers (p < 0.001). (c) Concentration of 
glucose (from 187 ± 6 mg/dL at 0 min to 174 ± 10 at 180 min, p = 0.003) and (d) lactate (0.6–0.7 mmol/L 
at 180 min, p < 0.001) significantly changed during reperfusion. PAP, pulmonary artery pressure; 
Ppeak, peak inspiratory pressure. One-way repeated measures ANOVA; Tukey’s multiple 
comparison test. p < 0.05: a = vs 0 min; b = vs 30 min; c = vs 90 min; d = vs 120 min; e = vs 150 min. 
2.2. Protein Profiles of Frozen Tissue Lung Lobes 
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All of the thirty protein lists of biological and technical replicate analyses were aligned through 
an in-house Multidimensional Algorithm Protein Map (MAProMa) tool [29,30] and grouped by 
calculating, for each distinct protein, the identification frequency and the average Spectral Counts 
(SpC*) and Score (Score*), which are useful parameters for relative abundance protein assessment in 
label-free quantitative approaches. In fact, SpC represents the total number of MS/MS spectra 
assigned to each protein and, consequently, it reflects protein relative abundance in each analyzed 
condition, while Score value is another semi quantitative parameter calculated by the integration of 
several search engine variables. Overall, 1895 distinct proteins were identified: 1588, 1616 and 1330 
for native, pre- and post-EVLP, respectively. A complete list of the identified proteins is reported in 
Supplementary Table S2. Figure S1a) shows the proportional Venn diagram of specific proteins for 
each condition. In particular, 1160 proteins were identified in all conditions, while 205 proteins were 
identified in both native and pre-EVLP, 75 proteins were common to pre- and post-EVLP, and 39 
proteins were identified in both native and post-EVLP conditions. Finally, a total of 184, 176 and 56 
distinct proteins were exclusively detected in native, pre- and post-EVLP, respectively. Using the 
MAProMa software it was also possible to plot each experimental condition list on a 2D virtual map, 
according to the theoretical Molecular Weight (MW) and Isoelectric point (pI) of identified proteins. 
An example is shown in Figure S1b), where the protein list of a post-EVLP sample was mapped. For 
each protein, a color/shape code was used according to the confidence of identification. 
2.3. Data Handling 
2.3.1. Repeatability 
Technical and biological repeatability of the method was tested by plotting SpC values of lists 
previously aligned with MAProMa; specifically, each technical replicate showed linear correlation 
(R2) and slope close to the theoretical value of 1 (Figure 3 and Supplementary Table S3). Figure 4a 
reports the technical repeatability of a sample from the native group. Similarly, the biological 
repeatability was verified (Supplementary Table S3 and Figure 3). As shown in Figure 4b, the average 
SpC of sample IIIM21 (X axis) was compared with that of IIIN23 (Y axis), both belonging to the post-
EVLP condition: R2 = 0.946 and y = 0.962. These findings demonstrated the good repeatability of the 
proteomic approach adopted, because the reduced oscillations of SpC values are a robust starting 
point for subsequently label-free investigations on protein profiles. Furthermore, similar results were 
also reported for all the analyzed samples (data not shown), except for sample IE9 (belonging to the 
post-EVLP condition) which shows a lower biological repeatability compared to the other samples in 
the same condition. An example of low biological repeatability with sample ID7 was reported in 
Figure 4c. For this reason sample, IE9 was further investigated and only 30 proteins (out of 1187) 
resulted significantly scattered in IE9 (compared to the other post-EVLP samples); in particular, these 
nonlinear proteins were mainly related to plasma proteins. Of note, deleting the plasma related 
proteins identified in the IE9 sample the correlation with the other post-EVLP samples improved 
(Figure 4d). For these reasons, the IE9 sample was taken into account for label-free quantitation and 
network analysis. The proteomics finding in the IE9 sample were in agreement with its different 
agonal phase as reported in Section 2.1. The different behaviors of the IE9 sample (both biological 
and molecular) could be correlated to possible lesions due to the supplemental manipulation (double 
cannulation required) that occurred to IE9 during the surgical procedure. 
Molecules 2018, 23, 3061 6 of 20 
 
 
Figure 3. Technical and biological repeatability of proteomic analysis. Diagrams of correlation 
coefficient (R2) values of technical and biological replicates. Each R2 value of technical and biological 
replicates was assigned a color code, and the corresponding ranges associated to a chromatic scale 
were reported. The technical R2 value (^) was obtained comparing the spectral count (SpC) values 
from two runs of the same sample. Similarly, plotting the average SpC* values of two samples 
belonging to the same condition the biological R2 value was calculated. The numerical linear 
regression values (R2) for each comparison are reported in Supplementary Table S3. 
Figure 4. Examples of technical and biological repeatability of proteomic analysis. (a) Typical 
technical repeatability (IIIQ29 sample, native group). (b) Biological repeatability between two native 
samples (IIIM21 and IIIN23). (c) Biological repeatability of IE9 sample compared to ID7 (post-EVLP 
samples). (d) Biological repeatability of IE9 sample compared to ID7 without the scattered proteins 
(mainly plasma proteins). SpC*: Average spectral count value. 
2.3.2. Clustering and Linear Discriminant Analyses 
Protein lists obtained by the proteomics analyses of the three experimental conditions analyzed 
were processed by Linear Discriminant Analysis (LDA) [35] and 451 proteins with F ratio > 3.4 and 
p-value < 0.05 were selected as descriptors of features able to correctly discriminate the three groups 
(Supplementary Table S4). An oriented dendogram was obtained using all the average SpC protein 
values of the fifteen animals analyzed. As shown in Figure 5, all post-EVLP samples resulted 
segregated into a group and separated from native and pre-EVLP samples. Of note, observing the 
post-EVLP grouping more in detail, the IE9 sample, while remaining within the same cluster, shows 
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a slightly different trend than the other animals in the group and is localized on a separate branch, 
much closer to the pre-EVLP and native ones. 
 
Figure 5. Hierarchical clustering obtained by Linear Discriminant Analysis (LDA). Using the average 
SpC values from all conditions, the post-EVLP samples were correctly segregated and 451 descriptor 
proteins by LDA were identified. Of note, IE9 sample, although remaining within the correct 
subgroup, is localized on a separate branch. The complete list of descriptor proteins extracted by LDA 
is reported in Supplementary Table S4. filtering criteria. 
2.3.3. Differential Analysis 
Independently from cluster analysis, a label-free evaluation of differentially expressed proteins 
was also performed using two parameters available in MAProMa software and comparing the 
average SpC values obtained for each identified protein in the three examined conditions. These 
parameters are DAve (Differential Average) and DCI (Differential Coefficient Index) representing the 
ratio and the confidence in differential expression, respectively, of a protein between two samples. 
They allowed the identification of 239 distinct differentially expressed proteins (DEP), using the 
filters described in Material and Methods section (Section 4.4.3). In particular, 31 and 77 proteins 
resulted respectively down- and upregulated in pre-EVLP compared to native. On the other hand, 
180 resulted more abundant in pre-EVLP compared to post-EVLP, and only three proteins were 
upregulated in post-EVLP. Finally, 135 and 11 were down- and upregulated, respectively, in post-
EVLP compared to native. Noteworthy, the combination of the data obtained by the differential 
evaluation with LDA and DEP analysis allowed the identification of 499 proteins, among which, 190 
distinct proteins resulted common to the two methods applied. In fact, about 80% of DEP were 
confirmed by LDA. The complete list of differentially expressed proteins is reported in 
Supplementary Table S4, where proteins derived from the same gene were grouped. 
2.4. Network Analysis 
Proteins selected by LDA and DEP analyses were used to reconstruct a Protein–Protein 
Interaction (PPI) network of Rattus norvegicus involving 487 nodes and 7806 interactions for the 
investigation of the functional relationships among groups of proteins identified in our proteomic 
approach. Considered nodes were grouped into 25 distinct subnetworks based on their function 
and/or subcellular localization. These subnetworks were grouped into five distinct main groups: 
extracellular matrix, translation, cytoskeleton, cell cycle, and metabolism. The proteins displayed on 
the network are represented by a chromatic scale that reflects the relative abundance (SpC) of their 
expression. By means of Cytoscape [36] it is also possible to upload to the same metabolic network 
the results derived from the label-free differential analysis of pairwise comparison: native vs. pre-
EVLP (Supplementary Figure S2a), pre-EVLP vs. post-EVLP (Supplementary Figure S2b), and native 
vs. post-EVLP (Supplementary Figure S2c). The majority of subnetworks resulted mainly up- and 
downregulated in pre- and post-EVLP, respectively, compared to the native condition. Of note, some 
subnetworks, such as redox, PDIA (Protein Folding Drives Disulfide Formation), actin- and myosin-
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related proteins and vesicle-mediated transport seem unchanged in native vs. post-EVLP 
comparison; on the contrary, these subnetworks resulted up regulated in pre-EVLP. 
To further investigate more the modifications of proteome in response to the EVLP treatment, it 
was calculated for each protein its variations (modules) due to perturbation (native vs. pre-EVLP) 
and treatment (pre-EVLP vs. post-EVLP). Theoretically, if the two modules present similar values 
but they have opposite sign, the protein recovers its level to the reference (in our case native 
condition). The extraction of so-called “recovered proteins” was simplified by calculating the 
Proteome Remodeling index (PRi) for each protein using an unbiased procedure. In this way, we 
extracted 104 proteins, and 32 had a statistically significant result (ANOVA ≤ 0.05, Supplementary 
Table S5). Proteome Activated index (PAi) was calculated using baseline and treatment modules to 
extract proteins which unchanged between native and pre-EVLP conditions (perturbation module), 
but resulted to be activated or inhibited (up- or downregulated, respectively) with treatment (post-
EVLP condition). In this case 168 proteins were found, of which 67 resulted statistically significant by 
ANOVA (≤0.05) (Supplementary Table S6). Of note, only two proteins resulted increased with the 
EVLP treatment. These extracted proteins were uploaded in the PPI network previously prepared 
and four subnetworks resulted to be enriched (Figure 6 and Figure S3): myosin-related proteins, 
actin-related proteins, and vesicle-mediated transport (belonging to cytoskeleton), and redox-
processes (metabolism). Similar results were obtained by means of ln[FoldChange] (Supplementary 
Tables S5,6). 
 
Figure 6. Main pathways involved in the proteome remodeling induced by the EVLP procedure. 
Enriched subnetworks based on recovered and activated proteins after ANOVA (<0.05) and Tukey’s 
test (<0.05; * <0.08). These statistically significant proteins were previously extracted using an 
unbiased procedure that evaluated simultaneously the changes in the proteome in the three 
conditions: native, pre-EVLP, and post-EVLP. Recovered proteins, marked as a green/circle, were 
extracted using the Proteome Remodeling index (PRi); while activated proteins marked as 
red/triangle and blue/arrow for up- and downregulated in post-EVLP, respectively, were extracted 
using Proteome Activated index (PAi). The application of PRi and PAi filters highlights an enrichment 
in (a) vesicle-mediated transport, myosin-, and actin-related proteins, belonging to cytoskeleton and 
(b) redox regulation, belonging to metabolism. The blank nodes identify the protein descriptors 
resulted outside the applied PRi and PAi filters. (c) Summary of considered trends of remodeled 
proteins. The complete lists of PRi and PAi extracted proteins are reported in Supplementary Tables 
S5,6. 
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2.5. Comparison between Frozen and FFPE Tissue Lung Lobes 
Shotgun proteomics approach was also employed to compare frozen and FFPE lung tissues. In 
particular, three FFPE samples from the pre-EVLP condition were analyzed. Using MAProMa 
software the three FFPE resulting proteomes were aligned with the corresponding frozen ones. The 
resulting twelve nanoLC-MS/MS runs allowed the identification of 1764 distinct proteins: 1458 and 
1351 for frozen and FFPE, respectively (Table S7). As reported in Figure 7a more than 77% (1044) of 
FFPE proteins were confirmed in frozen specimens. Plotting the normalized average SpC values 
between the two datasets both R2 and slope were close to the theoretical value of 1 (Figure 7b). 
Finally, through the Protein ANalysis THrough Evolutionary Relationships (PANTHER) 
classification system [33] it was possible to classify proteins based on their molecular function. As 
shown in Figure 7c the distribution of proteins between the FFPE and frozen tissues was nearly 
identical, suggesting that the differences in proteins observed in the two datasets were not biased 
toward a specific molecular function. 
 
Figure 7. Comparison between frozen and FFPE pre-EVLP lung lobes. (a) Protein overlapping 
between frozen and FFPE in three pre-EVLP analyzed samples (IIL11, IIG13 and IIH15). (b) Plot of 
frozen vs FFPE samples using normalized average spectral count (SpC*) values. (c) Distribution of 
proteins between the frozen and FFPE according to their molecular function using Protein ANalysis 
THrough Evolutionary Relationships (PANTHER) classification system. For each molecular function, 
reported as percentage of proteins for the two tissues (blue/solid colour for frozen and blank for FFPE 
datasets), the difference frozen vs FFPE was <0.9%. 
3. Discussion 
Here, we employed a rat model and recent advances in MS-based proteomics to generate a 
proteomic system biology view of the EVLP procedure. The EVLP procedure cannot be solely 
evaluated on the basis of physiological measurements. In fact, analyses at the molecular level are 
mandatory to find potential protein markers for a better understanding of mechanisms by which 
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EVLP is ruled [18–20]. In light of this our approach represents a first attempt in this direction, with 
the intent to develop a shotgun label-free platform which could be helpful in extracting informative 
features from complex biospecimens in large scale analyses useful to correlate molecular expressions 
to biological processes. In particular, a nanoLC system based on chip technology was combined to a 
next-generation mass spectrometer with improved resolution and accurate mass detection in order 
to investigate protein extracts obtained from frozen lung tissues in three experimental groups (native, 
pre-EVLP and post-EVLP). This high throughput system was completely automatized and allowed 
the simultaneous identification of thousands of proteins with a wide range of concentrations and 
without limits of pI and MW [17,28] (see Figure 1). 
Moreover, the large amount of data produced were properly processed with dedicated, 
commercial or in-house, bioinformatic tools using parameters provided by the employed search 
engines [29–33]. In our case, data handling was greatly simplified by means of MAProMa software 
[29,30] since it allowed the automatic alignment of different protein lists, presenting the results in a 
user-friendly format and highlighting differentially expressed proteins. In addition, data dimensional 
reduction with support vector machines was also applied to extract informative features useful for 
the correct classification and sample grouping using only information correlated to them and their 
relationships [35]. In this respect, the hierarchical clustering analysis performed by LDA and 
conducted on the fifteen average protein lists obtained by the three examined conditions, permitted 
to discern the differences among them and to correctly group samples in the three distinct categories 
(Figure 5). These findings indicate the high reproducibility and statistical reliability of the proposed 
approach. An additional confirmation derived from the technical and biological repeatability results 
obtained comparing SpC values of protein lists of the same sample injected in replicate and of 
different animals belonging to the same experimental group (Figure 3). In this case, our platform was 
able to point out differences in the IE9 sample with respect to the other biological replicates of the 
post-EVLP group. Specifically, the IE9 sample showed a very low biological repeatability in all the 
comparisons with animals of the same experimental group (Figure 3c). With the aim of further 
understanding the IE9 molecular variability, the protein profiles of this animal and its biological 
replicates were investigated. The results of differential analysis showed a similar pattern of IE9 with 
the other post-EVLP animals except for only a few proteins that resulted up regulated and essentially 
related to blood components. These findings were in agreement with the longer agonal phase of this 
animal herein reported and could be correlated to possible lesions due to the double cannulation 
incurred during the surgical procedure. However, this did not compromise the final functional 
outcome of the animal, which was not excluded from the study, but with its unique profile revealed 
the potentiality of our platform as confirmed by clustering analysis (Figure 5). In contrast to the 
inability of functional measurements to detect even small differences, clustering correctly maintained 
IE9 within the post-EVLP group but underlined its incomplete alignment with the other components 
of the same group, providing in this way a deeper and more accurate data evaluation strategy. 
Another interesting feature that could be supported by our approach is the possibility to conduct 
a label-free quantitative investigation for the identification of potential biomarkers. Given the 
increasing popularity of EVLP treatment, the search for new molecular targets which could be 
employed in the future as objective parameters to recommend a protocol over others, to monitor the 
entire procedure and to predict lung performance is urgent. With this in mind, our study represents 
a first effort in this direction, as far as we know. In particular, LDA analysis showed the post-EVLP 
group completely segregated from the pre-EVLP and native conditions and provided the selection of 
451 proteins whose trends were able to discriminate the three groups (Figure 5). Using an 
independent methodology, supplied by the application of DAve and DCI parameters included in 
MAProMa software [29,30], 246 distinct differentially expressed proteins were found with an overlap 
of 80% with those previously extracted by LDA. 
At this point, the differentially expressed proteins resulting from both these computational tools 
were uploaded in a network built using Cytoscape [32] and with which it was possible to visualize 
protein–protein interactions and metabolic pathways mainly involved. As reported in the Results 
section, the differentially expressed proteins were network visualizable with a color code that 
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represented the DAve values resulting by the pairwise comparison of the three conditions 
(Supplementary Figure S2a–c). What emerged from a first observation was that EVLP treatment 
involved a downregulation of a great number of proteins reported in the metabolic pathways. If, from 
a functional point of view, both EVLP and native lungs seemed to achieve the same results in term of 
graft acceptability criteria, the study of molecular profiles suggests that this take place in different 
ways with the intervention of different pathways. Certainly, the experimental data permitted to 
exclude that this phenomenon was attributable to sample degradation due to a different processing 
time that the EVLP treatment required. In fact, the total number of identified proteins in the three 
conditions presented similar orders of magnitude and only 13% of the distinct identified proteins 
showed a differential expression (Supplementary Table S1). 
Moreover, by means of proteome remodeling indexes, PRi and PAi, proteomic changes were 
simultaneously evaluated in pre-EVLP and in post-EVLP, where proteome expression in the latter 
seems to return to the reference condition (native group). After EVLP treatment, approximately 32 
proteins resulted statistically significant in rebalancing the proteome to the reference condition of 
native lungs. Based on these findings it was possible to speculate that restored proteins might be 
correlated to the reconditioning effect exerted by EVLP. Of note, these proteins were always down 
regulated in post-EVLP compared to pre-EVLP; specifically, they resulted mainly involved in 
cytoskeleton (vesicle-mediated transport and myosin- and actin-related proteins) and in redox 
regulation (metabolism) (Figure 6). Another interesting class of proteins extracted by calculating the 
Proteome Activated index (PAi) did not show differential expression between native and pre-EVLP 
conditions, but increased or decreased their abundance after EVLP treatment. In particular only Mal2 
and SOD1 increased their level, while 65 proteins decreased their level in post-EVLP compared to 
both native and pre-EVLP groups. Similarly to PRi-extracted proteins, those PAi-extracted resulted 
being mainly involved in cytoskeleton (vesicle-mediated transport and myosin- and actin-related 
proteins) and in redox regulation (metabolism). 
To better understand these data and hypothesize possible mechanisms that govern the activation 
or suppression of metabolic pathways, we need to keep in mind what happens at a biochemical level 
during ex vivo lung perfusion. During the entire EVLP procedure, the lungs are subjected to a first 
phase of oxygen breakdown, for cold flushing and recruitment of organ (cold ischemia), and to a 
subsequent reperfusion by ex vivo perfusion/ventilation. The reduction of O2 causes alterations in 
cellular metabolism and the switch from aerobic to anaerobic metabolism [37] with the subsequent 
reduction of intracellular ATP. Alteration of cell pH and generation of reactive oxygen species (ROS) 
[38,39] due to increase of Na+ [40,41] and Ca2+ ions [42,43] are significant events that also occur. In 
addition, changes in cytoskeleton composition are signaled in endothelial cells with the activation of 
adhesion proteins [44] and others one involved in the maintenance of flexibility and adaptability of 
cytoskeleton during hypoxia [45]. 
As stated before, all these effects attributable to EVLP on different biomolecular pathways are 
easily observable in networks built with proteins highlighted for their differential expression and 
extracted by MAProMa, LDA and remodeling indexes. In particular, it is interesting to note that, 
among upregulated proteins in the post-EVLP condition, there are some belonging to the 
extracellular matrix (ECM), constituents of the basement membrane, and involved in inflammatory 
process and its regulation. Their secretion is stimulated by IL-1β and TNF-α [46,47] in order to repair 
the basement membrane, regenerating ECM around pulmonary fibroblasts and reconstituting 
epithelial tissue integrity after lung injury [47]. Of note, our coauthors of the Fondazione IRCCS Cà 
Granda Ospedale Maggiore Policlinico of Milan, in a work just published [22] and based on studies 
of gene expression on the same animal model samples, observed that IL-1β and TNF-α resulted 
upregulated in EVLP, due to lung injury resulting in the induction of ischemia by the surgical 
procedure, and activated the NF-kB complex. The occurrence of an inflammatory response together 
with other alterations at the proteomic level in lungs, in a rat model designed without the use of anti-
inflammatory drugs that could falsify results, is to be considered another small step towards the 
discovery of molecular mechanisms modulated by EVLP. 
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If on the one hand during riperfusion the activation of inflammatory processes leads to the 
expression of pro-inflammatory mediators (like IL-1β and TNF-α) [48,49] on the other hand 
stimulates the release of reactive oxygen species (ROS) [50–52]. Together with the involvement of 
redox regulation and heat shock response in our networks, the observed SOD1 increase during the 
EVLP treatment has just the purpose to decrease ROS levels and to neutralize ROS-dependent 
damage. This seems to perform a protective action to contrast the inflammatory effect triggered by 
the procedure itself and raises the possibility that EVLP donor lungs could be less immunogenic than 
standard ones. The regulation of described proteins can be considered in all respects an integral part 
of the mechanism of action of the EVLP treatment and it may explain at least in part its efficacy in 
restoring lung function, or, as suggested by Lonati et al. [22], the resistance to damage caused by 
ischemia/reperfusion occurrence after transplantation. Thus, these findings add new key information 
to the mechanism behind potential EVLP beneficial effects and encourage additional research to 
implement EVLP therapeutic interventions. If this is the case, unveiling the modes of action of EVLP 
on lung phenotype and its monitoring at the molecular level, may be crucial not only for improving 
the transplant procedure but also in providing a powerful tool in translational medicine and in the 
advancement of pulmonary physiology. In addition, the present study can provide useful 
information to implement ex vivo perfusion procedure of other solid organs. 
In order to give a more complete view of our workflow potential, we performed a preliminary 
proteomic characterization of FFPE tissues. In particular, we analyzed three FFPE samples belonging 
to the pre-EVLP condition in order to compare their protein profiles with corresponding frozen 
tissues. Despite the low overlap between FFPE and frozen datasets (around 60%), R2 and slope values 
plotting the normalized average SpC values of the two tissues resulted being close to 1 (Figure 7). 
This suggests that the differences in the two pools were only apparent and probably related to the 
effects of fixation. In fact, as proof of this, the molecular function distribution of the identified proteins 
between frozen and FFPE tissues was nearly identical and not biased toward a specific molecular 
function. The last finding opens up the possibility to work with FFPE tissues and to connect 
proteomic outputs with information on clinical outcomes. 
Obviously, these results are still to be considered as preliminary and must be thoroughly 
investigated; however, these results offer the possibility to generate with a proteomic platform an 
overview of what happens at the molecular level during the entire transplant procedure with the 
ability to track the pattern of target proteins. In this regard, our approach facilitates the extraction of 
signature proteins from large datasets and their distribution in multiple pathways and quantitative 
traceability without the need of labeling, make these proteins ideal targets in the biomarker validation 
phase. In fact, the ongoing developments of MS-based proteomic technologies combined to 
increasingly powerful bioinformatics tools are accelerating their employment as a valid alternative 
to traditional assay methods for a number of features including: increased sensitivity, cost 
containment and simultaneous recording of multiple biomarkers. 
Of course, our study represents a proof of principle with which we want to prove the potential 
of a shotgun proteomic platform in these investigations. However, animal model and sample size 
limit drawing any further conclusions on proteins and pathways discussed above. In the near future, 
it will be necessary to increase the cohort of study and translate to human specimens the experimental 
research in order to confirm the findings derived from animal models and to overcome possible 
drawbacks due to the incomplete overlap of data. 
Another interesting aspect will be represented by the possibility of using other biospecimens, in 
addition to lung tissues, for minimizing invasiveness without compromising diagnostic accuracy. In 
this respect, exosomes and extracellular vesicles (EVs) are attracting great interest. As reported by 
Vallabhajosyula et al. [53] in a study on the perfusate from EVLP lungs, understanding EVs biology 
may have important diagnostic and therapeutic implications in pulmonary medicine, expanding 
even more the potentiality of the EVLP model. 
4. Materials and Methods  
4.1. Experimental Proteomic Pipeline 
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Figure 1 shows a schematic overview of the protocol adopted to prepare frozen and FFPE tissue 
lung lobs prior to the nanoLC-MS/MS analysis. The protocol consists of different parts that will be 
described in detail below. 
4.2. Surgical Procedure and Frozen and FFPE Tissue Collection 
4.2.1. Animals and Experimental Groups 
The experiments were performed in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health, at the Center for 
Preclinical Investigation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. 
The experimental protocol was approved by the Italian Institute of Health (permit number: 1082-15). 
Adult Sprague–Dawley male rats (Charles River, Calco, Lecco, Italy) weighing 270 to 330 g were 
housed in a ventilated cage system (Tecniplast S.p.A., Varese, Italy) at 22 ± 1 °C, 55 ± 5% humidity, 
on a 12 h dark/light cycle, and were allowed free access to rat chow feed and water ad libitum. 
Rat were randomly assigned to one of the following experimental groups (n = 5 in each group). 
Following sacrifice of rats under general anesthesia, lungs were subjected to in situ cold flushing and 
were then retrieved (pre-EVLP group). In separate experiments, after in situ cold flushing, isolated 
lungs underwent ex vivo perfusion/ventilation for 180 min (post-EVLP group). Finally, in a third 
group lung biopsies were taken from animals in resting conditions (native group). Samples of 
perfusion fluid were collected at time intervals throughout EVLP procedure for gas analysis. Tissue 
biopsies were harvested to investigate lung edema and proteome. Specifically, right superior lobes 
were used for lung edema evaluation, right inferior lobes were snap-frozen and stored at −80 °C for 
proteomic analysis, and median lobes were added to 4% formalin at room temperature. 
4.2.2. Ex Vivo Lung Perfusion (EVLP) 
Anesthesia, in situ flushing and lung procurement were performed according to our previous 
work. Briefly, after sacrifice, lungs were flushed with ice-cold Perfadex® (XVIVO Perfusion AB, 
Gotebörg, Sweden). Thereafter, the heart-lungs block was procured and connected to an isolated lung 
perfusion system (Hugo Sachs Elektronik, Harvard Apparatus, GmbH, March-Hugsstetten, 
Germany) primed with in-house acellular solution with extracellular electrolyte composition [21]. No 
treatment with corticosteroids or other anti-inflammatory drugs was performed. 
The protocol for rat ex vivo lung perfusion included a reperfusion phase (from 0 to 40 min) 
during which the lungs were gradually re-warmed, ventilated and perfused in order to avoid 
hemodynamic stress, and a steady-state phase (from 40 to 180 min). Specifically, initial pulmonary 
artery flow was set at 20% of target value and was then augmented over 40 min. Lung temperature 
was enhanced up to 37 °C in a 25 min time-span. Volume-controlled ventilation was started when 
the lungs reached a normothermic state, with respiratory rate of 35 bpm and pulmonary end 
expiratory pressure (PEEP) at 3 cmH2O. Initial tidal volume was set at 5 ml/kg and was increased up 
to 7 ml/kg in 10 min. 
4.2.3. Lung Function 
 Pulmonary artery and airway pressure assessment. 
PAP and Ppeak were continuously recorded, and digitally stored via an amplifier (data acquisition 
software Colligo Elekton, Milan, Italy). 
 Gas analysis and determination of glucose and lactate concentration. 
Gas analysis, glucose, and lactate concentration evaluation were performed on perfusate samples 
using a gas analyzer (ABL 800 FLEX, A. De Mori Strumenti, Milan, Italy). 
 Lung edema index. 
At the end of the procedure, the right superior lobe was weighed (KERN & SOHN GmbH, Balingen, 
Germany), before (wet) and after (dry) storage at 50 °C for 24 h (LTE Scientific, Oldham, UK). Wet-
to-dry ratio (W/D) was then calculated and used as index for pulmonary edema. 
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4.3. Protein Extraction 
4.3.1. Frozen Lobes 
For proteomic analysis of frozen samples, each lobe was suspended in 300 µL 0.1 M H4HCO3 pH 
7.9 buffer with 10% acetonitrile (Sigma-Aldrich Inc., St Louis, MO, USA) and homogenized in ice. 
The protein concentration was assayed using dotMETRICTM (G-Biosciences, St. Louis, MO, USA) and 
the membrane proteins were solubilized by adding RapigestTM SF reagent (Waters Co, Milford, MA, 
USA) at the final concentration of 0.33% (w/v). The resulting suspensions were incubated under 
stirring at 100 °C for 5 minutes. The digestion was carried out on 50 ± 0.5 µg proteins of each sample 
by adding Sequencing Grade Modified Trypsin (Promega Inc., Madison, WI, USA) at an 
enzyme/substrate ratio of 1:50 (w/w) overnight at 37 °C. An additional aliquot of 2 µg of trypsin (1:25 
w/w) was added in the morning, and the digestion continued for 4 h. Moreover, the addition of 0.5% 
Trifluoroacetic acid (TFA) (Sigma-Aldrich Inc., St Louis, MO, USA) stopped the enzymatic reaction, 
and a subsequent incubation at 37 °C for 45 min completed the RapiGest acid hydrolysis [54]. The 
water immiscible degradation products were removed by centrifugation at 13,000 rpm for 10 
minutes. Finally, the tryptic digest mixture was desalted using PepCleanTM C-18 spin column (Pierce, 
Rockford, Il, USA) and was resuspended in 0.1% formic acid (Sigma-Aldrich Inc., St. Louis, MO, USA) 
in water. Water was deionized by passing through a Direct Q (Millipore, Bedford, MA, USA). 
4.3.2. Formalin-Fixed Paraffin Embedded (FFPE) tissues 
Paraffin-embedded tissue sections were dewaxed by means of xylene deparaffinization. Briefly, 
each lung biopsy was cut up to obtain five 10 µm-sections from the same block. Slices were placed in 
a 1.5 ml collection tube and added to xylene (Sigma-Aldrich Inc., St Louis, MO, USA). Following 10 
min-incubation at room temperature, samples were centrifuged at 13,000 rpm for 2 min. Supernatants 
were discarded and pellets underwent two additional xylene washes. Next, samples were rehydrated 
using increasing ethanol dilutions (100%, 96%, and 70% ethanol, Sigma-Aldrich Inc., St Louis, MO, 
USA). Dry pellets were stored at −80 °C. 
The dewaxed tissues from 3 pre-EVLP samples (IIF11, IIG13 and IIH15), were solubilized in 
RapigestTM SF reagent at the final concentration of 0.25% (w/v) and incubated under stirring, first at 
100 °C for 20 minutes and then sequentially at 80 °C for 2 h. Then the protein concentration was 
assayed using dotMETRICTM, and 24 ± 2.1 µg of proteins from each sample was digested by 
Sequencing Grade Modified Trypsin at an enzyme/substrate ratio of 1:25 (w/w) overnight at 37 °C. 
An additional aliquot of 0.5 µg of trypsin (1:12,5 w/w) was added in the morning, and the digestion 
continued for 4 h. The enzymatic digestion was stopped with the addition of 0.5% TFA, and a 
subsequent incubation at 37 °C for 45 minutes completed the RapiGest acid hydrolysis [54]. The water 
immiscible degradation products were removed by centrifugation at 13,000 rpm for 10 minutes. 
Finally, the tryptic digest mixture was desalted using PepCleanTM C-18 spin column and was 
resuspended in 0.1% formic acid in water. 
4.4. Proteomic Analysis 
4.4.1. Liquid Chromatography 
Trypsin digested mixture were analyzed using Eksigent nanoLC-Ultra® 2D System (Eksigent, 
part of AB SCIEX, Dublin, CA, USA) combined with cHiPLC®-nanoflex system (Eksigent) in trap-
elute mode. Briefly, samples were first loaded on the cHiPLC trap (200 µm × 500 µm ChromXP C18-
CL, 3 µm, 120 Å) and washed with the loading pump running in isocratic mode with 0.1% formic 
acid in water for 10 minutes at a flow rate of 3 µL/min. The automatic switching of cHiPLC ten-port 
valve then eluted the trapped mixture on a nano cHiPLC column (75 µm × 15 cm ChromXP C18-CL, 
3 µm, 120 Å) through a 65 minute gradient of 5 to 40% of eluent B (eluent A, 0.1% formic acid in 
water; eluent B, 0.1% formic acid in acetonitrile) at a flow rate of 300 nL/min. Trap and column were 
maintained at 35 °C for retention time stability. 
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4.4.2. Mass Spectrometry 
MS spectra were acquired using a QExactive mass spectrometer (Thermo Fisher Scientific, San 
Jose, CA, USA), equipped with an EASY-Spray ion source (Thermo Fisher Scientific). Easy spray was 
achieved using an EASY-Spray Emitter (Dionex Benelux BV, Amsterdam, The Netherlands) 
(nanoflow 7 µm ID Transfer Line 20 µm × 50 cm) held to 2.1 kV, while the ion transfer capillary was 
held at 220 °C. Full mass spectra were recorded in positive ion mode over a 400 to 1600 m/z range 
with a resolution setting of 70,000 FWHM (Full Width at Half Maximum) (@ m/z 200) with 1 microscan 
per second. Each full scan was followed by 7 MS/MS events, acquired at a resolution of 17,500 FWHM, 
sequentially generated in a data dependent manner on the top seven most abundant isotope patterns 
with charge ≥2, selected with an isolation window of 2 m/z from the survey scan, fragmented by 
higher energy collisional dissociation (HCD) with normalized collision energies of 30 and 
dynamically excluded for 30 sec. The maximum ion injection times for the survey scan and the MS/MS 
scans were 50 and 200 ms and the ion target values were set to 106 and 105, respectively. 
The MS data have been deposited to the ProteomeXchange Consortium via the PRIDE [55] 
partner repository with the dataset identifier PXD006692. 
4.4.3. Data Handling 
All data generated were processed using the SEQUEST search engine [56] of BioWorks platform 
(version 3.3.1, University of Washington, licensed to ThermoFinnigan Corp., San Jose, CA, US). The 
experimental MS/MS spectra were correlated to tryptic peptide sequences by comparison with 
theoretical MS/MS spectra obtained by in silico digestion of the Rattus norvegicus protein database 
(about 79609 entries), downloaded (January 2014) from the National Centre for Biotechnology 
Information (NCBI) website (www.ncbi.nlm.nih.gov). This allowed the identification of peptide 
sequences and related proteins. The confidence of protein identification, particularly when using data 
from a single peptide, was assured by applying stringent filtering criteria: the MS/MS tolerance was 
set to 1.00 Da; the precursor ion tolerance was set to 50 ppm (part-per million); and the intensity 
threshold was set to 100. Moreover, searches were performed with no enzyme. Finally, to assign a 
final score to the proteins, the SEQUEST output data were filtered by setting the peptide probability 
to 1 × 10−3, the chosen minimum correlation score values (Xcorr) were 1.5, 2.0, 2.5, and 3.0 for single-, 
double-, triple-, and quadruple-charged ions, respectively, and the consensus score higher than 10 
(FDR < 0.01). The output data obtained from the SEQUEST software were aligned, compared and 
grouped by calculating the average Spectral Count (SpC*) and Score values for each distinct protein 
using an in-house algorithm, namely, the Multidimensional Algorithm Protein Map (MAProMa) 
[29,30]. 
4.4.4. Label-Free Differential Analysis 
Differential analysis was performed by comparing the average Spectral count (SpC*) values of 
each protein, obtained from native, pre-EVLP and post-EVLP lungs, using Dave and DCI algorithm 
inserted in the MAProMa software. DAve is an index of the relative ratio between the two compared 
protein lists and DCI is an index to evaluate the confidence of DAve. Most confident uprepresented 
proteins in lung tissues showed a DAve ≥ +0.2 and a DCI ≥ +10; most confident downrepresented 
proteins showed a DAve ≤ −0.2 and DCI ≤ −10. 
4.4.5. Hierarchical Clustering and Linear Discriminant Analysis 
Biological replicates were evaluated using an unsupervised learning method, such as 
hierarchical clustering (HC) [57] using in-house R-scripts, which was based on the XlsReadWrite, 
clue, and clValid libraries (http://cran.r-project.org). In particular, the Euclidean distance metric was 
applied, and an Agglomerative Coefficient was calculated (Agglomerative Nesting—AGNES). 
AGNES, which as additional information, yields the AC that measures the amount of clustering 
structures found. AC is a dimensionless quantity, which could vary between 0 (bad structure) and 1 
(very clear structuring). In order to perform multivariate analysis, all protein lists were processed 
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using Linear Discriminant Analysis (LDA) [35]. This analysis was applied by using a common 
covariance matrix for all the groups and the Mahalanobis distance [58] from each point to each 
group’s multivariate mean (proteins derived from the same gene were grouped). The identifying 
features (proteins) that discriminated the analyzed samples were considered to be those with the 
largest F ratio (>3.4) and the smallest p-value (<0.05). Specifically, the F ratio represented the model 
mean square divided by the error mean square, whereas the p-value indicated the probability of 
obtaining an F value greater than that calculated if, in reality, there was no difference between the 
population group means. 
4.4.6. Network Analysis 
Starting from the list of experimentally identified proteins, the corresponding Rattus norvegicus 
Protein-Protein Interaction (PPI) network was extracted. By means of a Cytoscape plug-in, STRING 
8 database (http://string.embl.de/) [36], known interactions were retrieved from several databases 
such as Prolink, DIP, KEGG, BIND and others. All types of interactions were retrieved from each 
repository without applying a p-value threshold. Protein–DNA, protein–RNA, protein–metabolite, 
and protein–drug interactions, if present in the data sets, were removed, as were duplicates and self-
interactions. PPI were examined using Cytoscape 3.2.1 (http://www.Cytoscape.org) [32] by applying 
a score >0.15. Protein–DNA, protein–RNA, protein–metabolite, and protein–drug interactions, if 
present in the data sets, were removed, as were duplicates and self-interactions. PPI were processed 
using Cytoscape 3.2.1 (http://www.cytoscape.org/) [32]. Proteins that were not mapped or were 
mapped as isolated components were not considered in the analysis. Bingo 2.44 [59], a Cytoscape 
plug-in, was used to emphasize subnetworks based on functionally organized GO terms, and the 
MCODE plug-in [60] was used to cluster subnetworks based on their topology and, specifically, by 
considering densely connected regions. Further selection of nodes was made by means of evaluation 
of baseline, perturbation and treatment modules, using Dave or ln[FoldChange] values to calculate 
PRi and PAi parameters. 
4.4.7. Proteome Recovery and Proteome Activation Index 
For each protein it was evaluated its variations (modules) due to perturbation (native vs pre-
EVLP) and/or treatment (pre-EVLP vs post-EVLP); if the two modules present similar values but 
opposite sign, the protein recovers its level to the reference (in our case native condition). The 
extraction of so-called “recovered proteins” was simplified by calculating the Proteome Remodeling 
index (PRi) for each protein using an unbiased procedure. The PRi is calculated by the following 
formula, 
PR  =
M(b − p) 
M(p − t) 
 
Where J: each identified protein. M(b-p)J: Perturbation Module = Difference native vs pre-EVLP (b: 
baseline; p: perturbed); differential abundance of specific protein J comparing baseline vs perturbed 
(pre-EVLP) conditions. M(p-t)J: Treatment Module = Difference pre-EVLP vs post-EVLP (t:treated); 
differential abundance of specific protein J comparing perturbed (pre-EVLP) vs treated (post-EVLP) 
conditions. 
Theoretically, if protein level after treatment remodeled to reference (native) the two modules 
(perturbation and treatment) should have similar value and opposite sign; then the PRi will be 
negative and close to unit (−1). In our case, we considered proteins with a PRi in the range −0.5 to −2. 
Also, using a variant of PR index, called Proteome Activated index (PAi), it was extracted unchanged 
proteins between native and pre-EVLP conditions (perturbation module), but activated or inhibited 
(up- or downregulated, respectively) with treatment (post-EVLP condition). The related formula, 
based on baseline and treatment modules, is 
PA  =
M(t − b) 
M(p − t) 
~ − 1 
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M(t-b)J: Baseline Module = Difference post-EVLP vs. native (t: treated condition, post-EVLP); 
differential abundance of specific protein J comparing treated (post-EVLP) vs. baseline conditions. 
Differential abundance of each module may be expressed as DAVE value, from MAProMa algorithm 
or ln[fold change]). However, because in some case the fold-change calculation returns non-sense 
values (such as n/0 or 0/n), we preferred to use DAVE value to calculate modules. Moreover, 
MAProMa platform permits the filtration by absolute variation, using DCI algorithm, excluding very 
low expressed protein (very low spectral count, multiple DCI < 5) confusingly with noise. 
4.5. Statistics 
Sample size was determined considering a statistical test power of 0.80 and an alpha value of 
0.05. Results indicated that a sample size of 15 animals (n = 5 per group) would enable to detect a 
minimum difference in protein expression of 0.35 with an expected standard deviation of 0.15. 
To detect outliers, Grubb’s test was applied for each parameter. A probability value <0.05 was 
considered significant. Baseline characteristics and trends of PAP, Ppeak, glucose, and lactate during 
ex vivo perfusion were analyzed by means of one-way analysis of variance (ANOVA) followed by 
Tukey’s multiple comparison test. All analyses were performed using Sigma Stat 11.0 dedicated 
software (Systat Software Inc., San Jose, CA, USA). 
Identified protein were evaluated by LDA (F ratio > 3.4 and a p-value < 0.05) [61] and MAProMa 
(confidence thresholds were set as DAve ≥ 0.2 and a DCI ≥ 10) platforms. 
Finally, proteins extracted by PRi and PAi algorithms were statistically evaluated by ANOVA 
and Tukey’s test. 
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